New hope for ITP patients: which Second-Line therapy works best?
NCT ID NCT07051915
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests two treatments for adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants will receive either avatrombopag (a daily pill) or rituximab (an infusion) to see which better raises platelet counts and improves quality of life. The goal is to find a more effective second-line option after steroids fail.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA PURPURA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.